Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
10 Companies to Watch in 2026
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.
Six Biotechs to Watch in 2026: Breakthroughs, Setbacks, and Big Turning Points Ahead
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
10 Companies to Watch in 2026
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.
10 Companies to Watch in 2026
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.
Six Biotechs to Watch in 2026: Breakthroughs, Setbacks, and Big Turning Points Ahead
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
Poolbeg Pharma (AIM: POLB) Letter to Shareholders – 2025 a year of progress
Letter to Shareholders – 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected
Poolbeg Pharma (AIM: POLB) POLB 001 to feature in CRS research programme
POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part
Poolbeg Pharma (AIM: POLB) secures European patent for POLB 001
Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II
Zak Mir interviews Poolbeg Pharma’s CEO Jeremy Skillington & Principal Scientist Liam Tremble
Poolbeg Pharma PLC (AIM: POLB, OTC: POLBF) Chief Executive Officer Jeremy Skillington and Principal Scientist Liam Tremble talked with Share Talk’s Zak Mir about the company’s conference season.
European Green Transition (AIM: EGT) Option Agreement to Sell Pajala Copper Project
European Green Transition (AIM: EGT), a company seeking to acquire and transform revenue stage businesses supporting the green energy transition in Europe, announces that it has entered into an exclusive
European Green Transition (AIM: EGT) Appointment of Independent Non-Executive Director
European Green Transition (AIM: EGT), a company seeking to acquire and transform revenue stage businesses supporting the green energy transition in Europe, announces the appointment of Mick Kearney as an